Bullish Case: AI price forecast +3.5% supports a mild positive drift. The ADPT historical return surface shows a sizable mass of outcomes in the modest upside for shorter horizons, with tail risk in longer windows. Near-term SPY IV implies chop but not collapse. Insider selling by the COO is a caution sign, yet MRD growth, clonoSEQ Medicare expansion, and Genentech/Microsoft partnerships provide potential upside. Bias toward a controlled bounce rather than a volatile spike.

Bearish Case: Backwardation in ADPT options and outsized put volume signal hedging and risk-off pricing. Insider selling by the COO raises caution. MRD revenue growth and Medicare coverage remain uncertain; Genentech/Microsoft partnerships create exposure to partner performance. A negative MRD uptake or slower profitability could push ADPT toward the low end of recent trading ranges.

Potential Outcomes:

1. Upside (+10% to +30%): 42%. Catalysts: MRD growth, Medicare coverage expansion, and the AI price forecast.
2. Chop (−5% to +5%): 25%. Range-bound with hedging pressure; SPY IV remains elevated but not explosive.
3. Bearish (-20% to −35%): 23%. Put-demand dominates on disappointment or slower MRD uptake; downside risk to 11–12 range.
4. Big surge (+40% to +80%): 10%. A strategic deal/upgrade and stronger MRD momentum trigger a sharp repricing.

May 20, 2026